Kirk E Evoy1,2, Megan D Morrison3, Stephen R Saklad3. 1. College of Pharmacy, The University of Texas at Austin, 7703 Floyd Curl Dr., MC 6220, San Antonio, TX, 78229-3900, USA. evoy@uthscsa.edu. 2. University Health System, 1055 Ada Street, San Antonio, TX, 78223, USA. evoy@uthscsa.edu. 3. College of Pharmacy, The University of Texas at Austin, 7703 Floyd Curl Dr., MC 6220, San Antonio, TX, 78229-3900, USA.
Abstract
BACKGROUND: Gabapentinoid (pregabalin and gabapentin) abuse is increasingly being reported. OBJECTIVE: To assess the extent of gabapentinoid abuse, characteristics of typical abusers, patterns of abuse, and potential harms in order to bring this trend to providers' attention. METHODS: A systematic review of MEDLINE, Cochrane Library, ClinicalTrials.gov, and US FDA data, indexed through 28 July 2016, utilizing the following searches: pregabalin OR gabapentin OR gabapentinoid AND one of the following: abuse, misuse, overdose, or substance-related disorders[MESH], was conducted. Additional studies were identified through review of references. English-language epidemiological studies, clinical studies, and case reports/series of gabapentinoid abuse/misuse/overdose were included. The authors reached consensus regarding study inclusion after full-text review. The body of literature was assessed for bias qualitatively. RESULTS: Fifty-nine studies were included in this systematic review (24 epidemiological, three clinical abuse liability, 16 abuse/misuse/dependence case reports/series, 17 acute overdose case reports/series-one included both an epidemiological study and case series and was included in both counts). Analysis of these studies indicates increasing numbers of patients are self-administering higher than recommended doses to achieve euphoric highs. In the general population, a 1.6% prevalence of gabapentinoid abuse was observed, whereas prevalence ranged from 3% to 68% among opioid abusers. An international adverse event database identified 11,940 reports of gabapentinoid abuse from 2004-2015, with >75% reported since 2012. Risk factors include a history of substance abuse, particularly opioids, and psychiatric co-morbidities. While effects of excessively high doses are generally non-lethal, gabapentinoids are increasingly being identified in post-mortem toxicology analyses. CONCLUSION: Evidence suggests gabapentinoids possess potential for abuse, particularly in individuals with a history of opioid abuse, and reports of such abuse are increasingly being documented. Prescribers should be aware of high-risk populations and monitor for signs of abuse.
BACKGROUND:Gabapentinoid (pregabalin and gabapentin) abuse is increasingly being reported. OBJECTIVE: To assess the extent of gabapentinoid abuse, characteristics of typical abusers, patterns of abuse, and potential harms in order to bring this trend to providers' attention. METHODS: A systematic review of MEDLINE, Cochrane Library, ClinicalTrials.gov, and US FDA data, indexed through 28 July 2016, utilizing the following searches: pregabalin OR gabapentin OR gabapentinoid AND one of the following: abuse, misuse, overdose, or substance-related disorders[MESH], was conducted. Additional studies were identified through review of references. English-language epidemiological studies, clinical studies, and case reports/series of gabapentinoid abuse/misuse/overdose were included. The authors reached consensus regarding study inclusion after full-text review. The body of literature was assessed for bias qualitatively. RESULTS: Fifty-nine studies were included in this systematic review (24 epidemiological, three clinical abuse liability, 16 abuse/misuse/dependence case reports/series, 17 acute overdose case reports/series-one included both an epidemiological study and case series and was included in both counts). Analysis of these studies indicates increasing numbers of patients are self-administering higher than recommended doses to achieve euphoric highs. In the general population, a 1.6% prevalence of gabapentinoid abuse was observed, whereas prevalence ranged from 3% to 68% among opioid abusers. An international adverse event database identified 11,940 reports of gabapentinoid abuse from 2004-2015, with >75% reported since 2012. Risk factors include a history of substance abuse, particularly opioids, and psychiatric co-morbidities. While effects of excessively high doses are generally non-lethal, gabapentinoids are increasingly being identified in post-mortem toxicology analyses. CONCLUSION: Evidence suggests gabapentinoids possess potential for abuse, particularly in individuals with a history of opioid abuse, and reports of such abuse are increasingly being documented. Prescribers should be aware of high-risk populations and monitor for signs of abuse.
Authors: Howard N Bockbrader; David Wesche; Raymond Miller; Sunny Chapel; Nancy Janiczek; Paula Burger Journal: Clin Pharmacokinet Date: 2010-10 Impact factor: 6.447
Authors: Hiba Alblooshi; Gary K Hulse; Ahmed El Kashef; Hanan Al Hashmi; Mansour Shawky; Hamad Al Ghaferi; Habiba Al Safar; Guan K Tay Journal: Subst Abuse Treat Prev Policy Date: 2016-05-13
Authors: Uzoma B Duru; Gauri Pawar; Jed A Barash; Liv E Miller; Indrani K Thiruselvam; Marc W Haut Journal: Ann Intern Med Date: 2018-11-06 Impact factor: 25.391
Authors: John A Harvin; Rondel Albarado; Van Thi Thanh Truong; Charles Green; Jon E Tyson; Claudia Pedroza; Charles E Wade; Lillian S Kao Journal: J Am Coll Surg Date: 2021-01-21 Impact factor: 6.113
Authors: Hibo H Abdi; Nathalie L Maitre; Kristen L Benninger; Mark E Hester; Jonathan L Slaughter Journal: Pediatr Neurol Date: 2019-02-21 Impact factor: 3.372
Authors: Marc-Alexandre Gingras; Anthony Lieu; Louise Papillon-Ferland; Todd C Lee; Emily G McDonald Journal: J Hosp Med Date: 2019-05-12 Impact factor: 2.960
Authors: Andrew I Geller; Deborah Dowell; Maribeth C Lovegrove; Jana K McAninch; Sandra K Goring; Kathleen O Rose; Nina J Weidle; Daniel S Budnitz Journal: Am J Prev Med Date: 2019-03-06 Impact factor: 5.043